Afuco™ Anti-Human NGF ADCC Recombinant Antibody (PG110), ADCC Enhanced (CAT#: AFC-659CL)

Anti-NGF ADCC Enhanced Antibody (PG110) is an ADCC enhanced antibody produced by our Afuco™ platform. PG110 is a monoclonal antibody that inhibits the effects of the naturally occurring substance, nerve growth factor (NGF). Phase I study to evaluate the safety, tolerability, and pharmacokinetics of PG110 (Anti-NGF Monoclonal Antibody) in patients with pain attributed to osteoarthritis of the knee.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 Effects of PG110 on CFA-induced heat and mechanical hypersensitivity.

Figure 1 Effects of PG110 on CFA-induced heat and mechanical hypersensitivity.

CFA treatment significantly decreased the mean ipsilateral PWL (A) and PWT (B) 5 days post treatment in 36 rats that were divided into four groups (vehicle group, n = 9; PG110 (10 µg/kg, n = 9); PG110 (30 µg/kg, n = 9) and PG110 (300 µg/kg, n = 9). The decrease in the mean ipsilateral PWL (A) and PWT (C), but not contralateral PWL (B) and PWT (D), was highly significant (P < 0.001) in all groups. Compared with vehicle (open columns), a single intravenous (via tail vein) administration of PG110 at 300 µg/kg (black columns) and 30 µg/kg (dark grey columns) caused a significant increase in the mean PWL at 48 h post post-drug treatment (A). This increase was highly significant for the doses of 300 µg/kg (P < 0.001) and 30 µg/kg (P < 0.01). However, the lowest dose (10 µg/kg) tested (light grey column) caused no significant change in the ipsilateral PWL. Note that PG110 at the doses tested (see above) had no effects on the mean contralateral PWL (B). Administration of PG110 at 300 µg/kg (black columns) also caused a significant increase in the mean ipsilateral (C), but not contralateral (D), PWT at 48 h post post-drug treatment.

Djouhri, L. (2016). PG110, a humanized anti-NGF antibody, reverses established pain hypersensitivity in persistent inflammatory pain, but not peripheral neuropathic pain, rat models. Pain Medicine, 17(11), 2082-2094.

Figure 2 Effects of PG110 on SNA-induced heat and mechanical hypersensitivity.

Figure 2 Effects of PG110 on SNA-induced heat and mechanical hypersensitivity.

The mean ipsilateral PWL (A) and PWT (C) was significantly decreased 7 days after the nerve injury in 18 rats that were divided into two groups (vehicle group, n = 9; and PG110 (300 µg/kg, n = 9)). The decrease in the mean ipsilateral PWL and PWT was highly significant (P < 0.001) in both groups (A and C). However, SNA caused no apparent change in the mean contralateral PWL (B) or PWT (D). A single intravenous (via tail vein) administration of PG110 at 300 µg/kg (black columns) had no effect on the ipsilateral PWL (A) or PWT (C) at 48 h post post-drug treatment. Indeed the mean ipsilateral PWL and PWT after drug treatment (black column) were similar to those after vehicle (open column). Note that PG110 had no effects on the mean contralateral PWL (B) or PWT (D).

Djouhri, L. (2016). PG110, a humanized anti-NGF antibody, reverses established pain hypersensitivity in persistent inflammatory pain, but not peripheral neuropathic pain, rat models. Pain Medicine, 17(11), 2082-2094.

ELISA

Figure 3 is a graph showing the binding of PG110 to human nerve growth factor (NGF) but not to human brain derived neurotrophic factor (BDNF), human neurotrophin 3 (NT-3) or human neurotrophin 4 (NT-4), as determined by ELISA.

Figure 3 is a graph showing the binding of PG110 to human nerve growth factor (NGF) but not to human brain derived neurotrophic factor (BDNF), human neurotrophin 3 (NT-3) or human neurotrophin 4 (NT-4), as determined by ELISA.

Inhib

Figure 4 is a graph showing inhibition of binding of NGF to the TrkA receptor by the PG 110 antibody, as determined by a radiolabeled ligand binding experiment.

Figure 4 is a graph showing inhibition of binding of NGF to the TrkA receptor by the PG 110 antibody, as determined by a radiolabeled ligand binding experiment.

Inhib

Figure 5 is a graph showing inhibition of binding of NGF to the p75(NTR) receptor by the PG 110 antibody, as determined by a radiolabeled ligand binding experiment.

Figure 5 is a graph showing inhibition of binding of NGF to the p75(NTR) receptor by the PG 110 antibody, as determined by a radiolabeled ligand binding experiment.

Inhib

Figure 6 is a graph showing the inhibitory effect of PG110 antibody on TF-1 cell proliferation stimulated by human NGF.

Figure 6 is a graph showing the inhibitory effect of PG110 antibody on TF-1 cell proliferation stimulated by human NGF.

Inhib

Figure 7 is a graph showing the inhibitory effect of PG110 antibody on TF-1 cell proliferation stimulated by rat NGF.

Figure 7 is a graph showing the inhibitory effect of PG110 antibody on TF-1 cell proliferation stimulated by rat NGF.

Inhib

Figure 8 is a graph showing the inhibitory effect of PG110 antibody on TF-1 cell proliferation stimulated by mouse NGF.

Figure 8 is a graph showing the inhibitory effect of PG110 antibody on TF-1 cell proliferation stimulated by mouse NGF.

FuncS

Figure 9 is a graph showing the effect of PG 110 antibody treatment on skin lesioning in rats.

Figure 9 is a graph showing the effect of PG 110 antibody treatment on skin lesioning in rats.


Specifications

  • Host Species
  • Humanized
  • Derivation
  • Humanized
  • Type
  • ADCC enhanced antibody
  • Species Reactivity
  • Human
  • Applications
  • ELISA, Inhib, FuncS
  • Related Disease
  • Osteoarthritis

Product Property

  • Purity
  • >95% by HPLC
  • Storage
  • Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C.

Applications

  • Application Notes
  • The antibody was validated for ELISA, Inhibition, Function Assay. For details, refer to Published Data.

Target

  • Alternative Names
  • NGF; Beta-NGF; HSAN5; NGFB

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Ngf"

Humanized Antibody

Human Antibody

CAT Product Name Application Type
TAB-244 Anti-Human HNGF Recombinant Antibody Neut, ELISA, IF, IP, FuncS, FC, ICC IgG4 - kappa
TAB-512MZ Human Anti-NGF Recombinant Antibody (TAB-512MZ) ELISA, RIA, FC, SPR, Inhib Human IgG
TAB-513MZ Human Anti-NGF Recombinant Antibody (TAB-513MZ) ELISA, RIA, FC, SPR, Inhib Human IgG
TAB-512MZ-F(E) Human Anti-NGF Recombinant Antibody; Fab Fragment (TAB-512MZ-F(E)) ELISA, RIA, FC Human Fab
TAB-513MZ-F(E) Human Anti-NGF Recombinant Antibody; Fab Fragment (TAB-513MZ-F(E)) ELISA, RIA, FC Human Fab

Chicken IgY Antibody

CAT Product Name Application Type
BRD-0852MZ Chicken Anti-NGF Polyclonal IgY ELISA Chicken antibody
BRD-1134MZ Chicken Anti-Beta NGF Polyclonal IgY ELISA, WB, IHC Chicken antibody

Rabbit Monoclonal Antibody

Blocking Antibody

CAT Product Name Application Type
NEUT-1768CQ Recombinant Mouse Anti-NGF Antibody (aD11) IF, BL, ELISA, IHC IgG1, κ
NEUT-1772CQ Recombinant Mouse Anti-NGF Antibody (25623.1) Dot, ELISA, Inhib IgG1

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-025ML Afuco™ Anti-NGF ADCC Recombinant Antibody (Frunevetmab), ADCC Enhanced ELISA, IHC, FC, IP, IF, Inhib ADCC enhanced antibody
AFC-TAB-031ML Afuco™ Anti-NGF ADCC Recombinant Antibody (Ranevetmab), ADCC Enhanced ELISA, IHC, FC, IP, IF, Inhib ADCC enhanced antibody
AFC-TAB-111 Afuco™ Anti-NGF ADCC Recombinant Antibody (Tanezumab), ADCC Enhanced IF, IP, Neut, FuncS, ELISA, FC ADCC enhanced antibody
AFC-TAB-110 Afuco™ Anti-NGF Recombinant Antibody (AFC-TAB-110), ADCC Enhanced FC, IP, ELISA, Neut, FuncS, IF Human IgG1, κ

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for AFC-659CL. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare